Combinatorial Enzyme Therapy Against ESKAPE Pathogenic Biofilms
- 1st Edition - November 1, 2026
- Latest edition
- Editors: Awanish Kumar, Aditya Upadhyay
- Language: English
Combinatorial Enzyme Therapy Against ESKAPE Pathogenic Biofilms offers the latest insights into ESKAPE pathogen biofilms, including their formation, structure, and resist… Read more
World Book Day celebration
Where learning shapes lives
Up to 25% off trusted resources that support research, study, and discovery.
Description
Description
Combinatorial Enzyme Therapy Against ESKAPE Pathogenic Biofilms offers the latest insights into ESKAPE pathogen biofilms, including their formation, structure, and resistance mechanisms and highlights innovative therapeutic strategies to combat them, with a specific focus on combinatorial enzyme therapies. The book begins with an overview of the significant burden these pathogens impose across healthcare and the food industry, laying the groundwork for understanding the intricate relationship between antibiotic resistance and biofilm dynamics. It advocates novel approaches through combinatorial enzymatic therapy, detailing the mechanisms and synergies of various enzymes in effectively dismantling biofilms. With insights into cutting-edge delivery systems, including nanotechnology and the integration of CRISPR-Cas systems and artificial intelligence, the book charts a course for the future of advanced therapeutic strategies. It concludes by addressing regulatory considerations, positioning combinatorial enzyme therapy as a promising frontier in the fight against persistent infections caused by ESKAPE pathogens
Key features
Key features
- Provides a comprehensive understanding of the mechanisms behind biofilm formation and its role in antimicrobial resistance in ESKAPE pathogens
- Explores actionable strategies through combinatorial enzyme therapies, offering novel tools to dismantle biofilm matrices and enhance treatment outcomes
- Bridges the gap between research and clinical application by delivering practical insights that enable the adoption of enzyme-based solutions in real-world scenarios
Readership
Readership
Researchers, graduate and post graduate students, in microbiology, applied microbiology, and biotechnology engaged in the study ESKAPE pathogens, biofilm development, antimicrobial resistance, and therapeutics to combat them; health professionals treating bacterial infections and antimicrobial resistance
Table of contents
Table of contents
1. Introduction to Biofilm and Antibiotic Resistance in ESKAPE Pathogen-Associated Diseases: Clinical Burden and Challenges
2. Burden of ESKAPE Pathogens in the Food Industry
3. Co-relationship between Antibiotic Resistance and ESKAPE Pathogen Biofilm Formation
4. The Necessity of Combinatorial Enzymatic Therapy for ESKAPE Pathogen Biofilm Control
5. Mechanisms of Combinatorial Enzyme Therapy against the ESKAPE Pathogen Biofilm
6. Combinatorial Enzyme against ESKAPE Pathogen Biofilms: Carbohydrase, Protease, and Lipase Synergies
7. Combinatorial Nuclease Enzymes against ESKAPE Pathogen Biofilms with Clinical Application
8. Therapeutic Enzymatic Repurposing against the ESKAPE Pathogen Biofilm with Clinical Application
9. Nano Delivery of the Combinatorial Enzymes against the ESKAPE Pathogen Biofilm
10. CRISPR-Cas Systems and Artificial Intelligence Drive Combinatorial Enzyme Therapy against the ESKAPE Pathogen Biofilm
11. Future of Advanced Combinatorial Enzyme Therapy with Regulatory Aspects against the ESKAPE Pathogen Biofilm
2. Burden of ESKAPE Pathogens in the Food Industry
3. Co-relationship between Antibiotic Resistance and ESKAPE Pathogen Biofilm Formation
4. The Necessity of Combinatorial Enzymatic Therapy for ESKAPE Pathogen Biofilm Control
5. Mechanisms of Combinatorial Enzyme Therapy against the ESKAPE Pathogen Biofilm
6. Combinatorial Enzyme against ESKAPE Pathogen Biofilms: Carbohydrase, Protease, and Lipase Synergies
7. Combinatorial Nuclease Enzymes against ESKAPE Pathogen Biofilms with Clinical Application
8. Therapeutic Enzymatic Repurposing against the ESKAPE Pathogen Biofilm with Clinical Application
9. Nano Delivery of the Combinatorial Enzymes against the ESKAPE Pathogen Biofilm
10. CRISPR-Cas Systems and Artificial Intelligence Drive Combinatorial Enzyme Therapy against the ESKAPE Pathogen Biofilm
11. Future of Advanced Combinatorial Enzyme Therapy with Regulatory Aspects against the ESKAPE Pathogen Biofilm
Product details
Product details
- Edition: 1
- Latest edition
- Published: November 1, 2026
- Language: English
About the editors
About the editors
AK
Awanish Kumar
Dr. Awanish Kumar is an Associate Professor of the Department of Biotechnology at the National Institute of Technology, Raipur, Chhattisgarh, India. He has more than 13 years of research experience. He received his PhD in molecular parasitology from the CSIR-Central Drug Research Institute, Lucknow, India, and Jawaharlal Nehru University, Delhi, India, and completed his postdoctoral studies at McGill University, Montreal, Canada. His research interests are infection biology, drug targeting, and drug discovery.
Affiliations and expertise
Associate Professor and Head, Department of Biotechnology, National Institute of Technology Raipur, IndiaAU
Aditya Upadhyay
Aditya Upadhyay is a PhD Scholar at the Department of Biotechnology, National Institute of Technology in Raipur, India. His research focuses on infection biology, antibiotic resistance, and drug discovery in relation to biofilm formation. He holds a Master of Technology degree in Biotechnology (Honors) from Rajiv Gandhi Proudyogiki Vishwavidyalaya, Bhopal, India and a Bachelor of Technology in Biotechnology from Dr. A.P.J Abdul Kalam Technical University, Lucknow, India. Aditya is currently working on the design of new drugs and therapies to treat salmonella biofilm infections and combat antibiotic resistance. He has published articles in various SCI journals and contributed book chapters.
Affiliations and expertise
PhD Scholar, Department of Biotechnology, National Institute of Technology, Raipur, CG, India